Table 2.
Ghrelin antagonists | |||
Drug | Company | Target | Status |
TZP-301 | Tranzyme Pharma | Obesity, metabolic syndrome | Lead optimization |
Two families of ghrelin antagonists | Helsinn Pharmaceuticals | Obesity, metabolic syndrome | Lead optimization |
AEZS-123 | Aeterna Zenartis | Obesity, alcohol abuse | Preclinical |
Ghrelin antagonist | Novartis (Elixir) | Type 2 diabetes, obesity | Preclinical |